Information from Industry - Sponsored Supplement

A Second-Line Treatment Option for Hepatocellular Carcinoma

Developed under the direction and sponsorship of Exelixis, Inc. This content was peer reviewed by Federal Practitioner.

 

In this special supplement to Federal Practitioner, Dr. Binu John of the University of Miami discusses the challenges and treatment options for Hepatocellular Carcinoma (HCC), a common type of liver cancer, with a focus on patients with Child-Pugh B cirrhosis. It highlights the increasing incidence of liver cancer, especially in the context of cirrhosis caused by various factors, and the significance of early diagnosis and curative treatment in improving survival rates.

 

Click here to Read More

 

 

 

 

 

Next Article: